Background: Several drug-eluting stents (DES) have been demonstrated to significantly reduce the restensosis. It is not known, however, which of these DES, is more effective for long coronary lesion. Therefore, we performed a prospective randomized study comparing paclitaxel- (PES) and sirolimus-eluting stents (SES) for long coronary lesion (vessel size > 2.75mm. requiring long DES ��� 30 mm). Methods: Patients requiring long DES were randomly assigned to receive PES (Group I, n=100) or SES (Group II, n=101). The primary end point was in-segment late loss and the secondary end point was angiographic restenosis at 6 months and major adverse cardiac events (nonfatal myocardial infarction, death, target lesion revascularization) at 9 months. Results: The baseline clinical and angiographic characteristics were similar between the 2 groups. The lesion length and mean stent length were also similar between the 2 groups (Table 1). Procedural success was 99% in group I and 100% in group II. One in-hospital death occurred in group I. In-hospital events including myocardial infarction, target lesion revascularization, or stent thrombosis did not occurred. Six-month angiographic and nine-month clinical outcomes will be obtained until meeting. Conclusions: Treatment with PES or SES was safe and had a similarly short-term clinical outcome. The six-month angiographic and nine-month clinical outcomes will be presented at the meeting.